Please login to the form below

Not currently logged in
Email:
Password:

Former Novartis exec Richard Smith joins EMD Serono

He becomes senior vice president and head of US fertility and endocrinology

EMD Serono Richard SmithMerck KGaA's US biopharmaceutical business EMD Serono has appointed Richard Smith as senior vice president and head of US fertility and endocrinology.

Smith will take on responsibility for the two businesses as well as the firm's fertility technologies division, which launched its first medical device last year.

He joins EMD Serono from Novartis, where he spent the last 18 years in a series of roles across the company's commercial business, most recently as vice president and US head of sales and operations of its cardiovascular franchise.

Prior to this role, Smith served as executive director and head of Novartis' transplant franchise, as well as positions in customer segment marketing, strategy and commercial operations for specialty medicines, brand managed markets strategy, and pricing and contracting for its neuroscience franchise.

Gary Zieziula, president and managing director of EMD Serono, said: “We have a longstanding focus on providing comprehensive solutions in the areas of fertility and endocrinology care through innovative products as well as financial, educational and emotional support.

“Adding Richard's expertise, passion and industry knowledge to our strong and committed team will ensure that we are well-positioned to further meet the needs of patients and customers.”

25th January 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics